Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
:AVIR
AVIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.46 - $4.15
Previous CloseN/A
Volume180.19K
Average Volume (3M)382.87K
Market Cap
$298.67M
Enterprise Value-$169.36M
Total Cash (Recent Filing)$425.44M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 06, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding85,579,475
10 Day Avg. Volume336,722
30 Day Avg. Volume382,874
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.63K
Enterprise Value/Ebitda1.04
Forecast
1Y Price Target
$6.00Price Target Upside73.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMidstage hepatitis C trials have historically translated well to late-stage pivotal studies, supporting a bullish stance on Atea's drug potential.
Drug DevelopmentAtea's treatment is considered the best-in-class pan-genotypic regimen for hepatitis C cure, focusing on a short eight-week treatment duration with low potential for drug-drug interactions.
Financial PerformanceStrong financial position with $425.4M in cash, extending runway into 2028.
Bears Say
Financial EarningsAtea reported a net loss of $34.3 million, or a loss of $0.40 per share, which was similar to an estimate of a loss of $36.0 million, or a loss of $0.42 per share.
Workforce ReductionA workforce reduction by 25% is planned during the first quarter, which could lead to roughly $15 million in cost savings through 2027.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals, Inc.’s price range in the past 12 months?
Atea Pharmaceuticals, Inc. lowest stock price was $2.46 and its highest was $4.14 in the past 12 months.
What is Atea Pharmaceuticals, Inc.’s market cap?
Atea Pharmaceuticals, Inc.’s market cap is $298.67M.
When is Atea Pharmaceuticals, Inc.’s upcoming earnings report date?
Atea Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Atea Pharmaceuticals, Inc.’s earnings last quarter?
Atea Pharmaceuticals, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.025.
Is Atea Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Atea Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Atea Pharmaceuticals, Inc. pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
What is Atea Pharmaceuticals, Inc.’s EPS estimate?
Atea Pharmaceuticals, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has 85,579,475 shares outstanding.
What happened to Atea Pharmaceuticals, Inc.’s price movement after its last earnings report?
Atea Pharmaceuticals, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atea Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AVIR
Atea Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (73.41% Upside)
$6.00 (73.41% Upside)
Hedge Fund Trend
Increased
By 4.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.81%
12-Months-Change
Fundamentals
Return on Equity
-30.47%
Trailing 12-Months
Asset Growth
-20.44%
Trailing 12-Months
Company Description
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Atea Pharmaceuticals, driven by successful phase two trial results for the HCV program and a strong financial position. While there were challenges related to workforce reduction and cirrhotic patient recruitment, the company's strategic initiatives and financial health suggest a promising future.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$6.00
▲(73.41% Upside)
Technical Analysis
Astria Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Humacyte
―
Candel Therapeutics
―
Ownership Overview
9.51% Insiders
13.70% Mutual Funds
0.43% Other Institutional Investors
65.36% Public Companies and
Individual Investors